Introduction ments is the peptide-based fluoromethyl ketones, which are potent, irreversible inhibitors of cysteine proteases Cytotoxic T lymphocytes (CTL) rapidly kill target cells in (Sarin et al., 1996; Shaw, 1990) . These inhibitors, convitro using two effector pathways: a secretory pathway taining aspartic acid at the P1 site, are selective for involving exocytosis of preformed granules and the Fas caspases and do not block the aspartic acid-selective ligand (FasL)-Fas pathway, in which surface FasL on serine protease granzyme B (Sarin et al., 1996) . They CTL cross-links Fas on target cells . As are membrane permeable and nontoxic to cells and have both pathways can induce apoptotic changes in target been shown to block varied apoptotic death processes nuclei, it has been generally assumed that they share in intact cells, as shown in assays of both nuclear damdownstream biochemical events common to apoptotic age and cell lysis (Sarin et al., 1996; Jacobson et al., death . Experiments with inhibitors of caspases (Alnemri 1996; Pronk et al., 1996; Fearnhead et al., 1995) . (interleukin-1␤-converting enzyme [ICE] other type of caspase inhibitor used is the baculovirus family proteases) strongly implicate this enzyme family protein p35 (Clem et al., 1991) , which has been shown as a common mediator of apoptotic cell death (Henkart, to inhibit caspase-1 through caspase-4 but not gran -1996) , and it is an appealing hypothesis that caspase zyme B (Xue and Horvitz, 1995; Bump et al., 1995) . This activation is a common element in target cell death by protein inhibitor can be introduced into cells via transboth the granule exocytosis and Fas pathways.
fection or injection and has been shown to block various In support of this hypothesis, recent studies have proexamples of apoptotic cell death (Henkart, 1996) . vided direct molecular evidence for caspase activation
The results of this study show that caspases are not in both of these pathways. The CTL granule-derived required for target cell death via the CTL granule exoserine protease granzyme B has an unusual proteolytic cytosis pathway. Target cell lysis via the granule exospecificity requiring aspartic acid in the P1 position, cytosis pathway is not blocked by either class of caswhich is also the specificity required for caspase propase inhibitor, yet they block CTL-induced lysis by the cessing leading to activation. Accordingly, granzyme B FasL-Fas death pathway. However, caspase inhibitors has been shown by several laboratories to process and do effectively block nuclear damage induced by both activate many of the known caspases (Darmon et al., pathways. These results suggest that, while the gran-1995, 1996; Chinnaiyan et al., Duan et al., 1996;  zyme-activated caspases lead to apoptotic nuclear damage, caspases are not involved in target cell death Fernandes-Alnemri et al., 1996; Gu et al., 1996; Martin Thymocytes from B10 (solid lines) or lpr (broken lines) mice were tested as targets for cytotoxicity by allogeneic CTL (A and B) or FasL-bearing d11S CTL (C and D) in the presence of peptide-FMKs in a 4 hr chromium release assay. ZVAD-FMK, squares; BD-FMK, circles; ZFA-FMK, diamonds. In (A) and (B), when B10 thymocytes were used as targets, soluble anti-Fas IgG (10 g/ml) was added to the wells. Target lysis was measured by 51 Cr release (A and C), and nuclear morphology of targets marked with di-I-C 16 was assessed with Hoechst 33342 (B and D). In (A) and (C), error bars show the mean Ϯ SEM from three individual wells.
by the granule exocytosis pathway as they are in the other triggers of apoptotic death in thymocytes (Sarin et al., 1996) . The most striking finding was their inability Fas pathway.
to inhibit thymocyte lysis in Figure 1A .
Results

Peptide Caspase Inhibitors Block Tumor Cell Lysis Induced by Various Agents Peptide Caspase Inhibitors Block CTL-Induced Thymocyte Lysis via Fas but Not but Not CTL Granule Exocytosis
Since cytotoxicity experiments with CTL typically meaGranule Exocytosis Previous studies in our laboratory showed that two pepsure the lysis of tumor targets with the 51
Cr release assay, we tested the ability of the fluoromethyl ketone caspase tide inhibitors of caspases, BD-FMK (Boc-Asp(OMe)-fluoromethyl ketone) and ZVAD-FMK (Cbz-Val-Ala-Asp inhibitors to block lysis induced by several agents capable of inducing apoptotic death in tumor cells. Signifi-(OMe)-fluoromethyl ketone), specifically blocked apoptotic cell death in thymocytes, peripheral T cell blasts, cant lysis was not observed before 14 hr with these agents. The DNA topoisomerase I inhibitor camptoand T cell lines (Sarin et al., 1996) . In thymocytes, these two reagents were equally potent and completely thecin, the protein phosphatase inhibitor staurosporine, and the alkylating chemotherapeutic drug cisplatin, at blocked both apoptotic nuclear damage and cell lysis after 16 hr triggered by four independent input paththe concentrations used in Figure 2 , were found to induce apoptotic nuclear damage in greater than 50% of ways: corticosteroid, DNA damage by irradiation or etoposide, immobilized anti-Fas, and immobilized antiJurkat and L1210 cells by 18 hr, and this was blocked specifically by both ZVAD-FMK and BD-FMK (data not CD3. It was thus of interest to compare the ability of these caspase inhibitors to block CTL-induced death of shown). Figure 2 shows that peptide-FMK caspase inhibitors inhibited lysis of both Jurkat and L1210 tumors thymocytes by the granule exocytosis and FasL-Fas pathways (Figure 1 ). To examine the granule exocytosis induced by these agents. Unlike thymocytes, BD-FMK and ZVAD-FMK showed different relative potencies in pathway selectively, we incubated B10 thymocyte target cells with immunoglobulin G (IgG) anti-Fas or used lpr blocking such tumor death, correlating with the cell type rather than the stimulus (Sarin et al., 1996) , thymocytes. Apoptotic nuclear morphology induced at 4 hr by the CTL granule exocytosis pathway ( Figure 1B) The ability of peptide caspase inhibitors to block CTL killing of these tumor targets was also examined (Figure was specifically blocked by BD-FMK and ZVAD-FMK, with no effect of the control inhibitor ZFA-FMK (Cbz-3) by measuring lysis and CTL-induced apoptotic nuclear damage assessed by fluorescence microscopy or Phe-Ala-fluoromethyl ketone). In contrast with the blocking of CTL-induced apoptotic morphology by cas-DNA release after 4 hr. In Jurkat cells, caspase inhibitors effectively blocked the rapid CTL-induced lysis of cells pase inhibitors, lysis of thymocytes was not blocked ( Figure 1A) . Figures 1C and 1D show the effects of these via the FasL-Fas pathway induced by d11S CTL ( Figures  3C and 3D ). In contrast, when traditional allo-CTL were caspase inhibitors on killing via the CTL-triggered FasLFas pathway in the same assay, using the FasL-bearing used with the Fas pathway blocked by IgG anti-Fas, these caspase inhibitors blocked apoptotic nuclear mor-CTL hybridoma d11S (Rouvier et al., 1993) . Caspase inhibitors specifically and completely blocked both tarphology but not the lysis of these target cells (Figures 3A and 3B) . Similar experiments were performed using get lysis and apoptotic nuclear morphology, consistent with recent reports showing a role for caspases in FasFas neg murine leukemia L1210 target cells to test the granule exocytosis pathway and a Fas pos L1210 transfectriggered death (Muzio et al., 1996; Na et al., 1996) . ZVAD-FMK and BD-FMK were equally potent in blocking tant to examine the Fas-FasL pathway with d11S effectors ( Figures 3E-3H ). For these experiments, apopapoptotic nuclear damage and Fas-mediated lysis of thymocyte targets, similar to the results obtained with totic nuclear damage was measured by target DNA release. As observed with Jurkat targets, the caspase and lysis of the transfected cells was measured using cotransfected ␤-galactosidase as a marker (Memon et inhibitors blocked apoptotic nuclear damage by both pathways (Figures 3F and 3H) , and effectively blocked al., 1995). In L1210-Fas cells ( Figure 5D ), expression of p35 dramatically reduced CTL-induced lysis by the Fas FasL-Fas-mediated lysis ( Figure 3G ), but failed to inhibit lysis induced by the granule exocytosis pathway ( Figure  pathway . However, when Fas neg L1210 cells were used as targets for the CTL granule exocytosis pathway, lysis 3E). It is interesting to note that the two peptide caspase inhibitors showed approximately equal potency in was not affected by p35 expression ( Figure 5A ). In contrast, apoptotic nuclear damage via granule exocytosis blocking CTL-induced damage, in contrast with their inhibition of lysis induced by other agents (Figure 2) .
as assessed by both nuclear morphology and DNA release was effectively inhibited by p35 expression (FigOverall, the results with CTL and the tumor target cells were essentially the same as with thymocyte targets.
ures 5B and 5C). Parallel experiments with p35 expression in Jurkat target cells yielded similar results, in that p35 expression inhibited Fas-mediated lysis but not the Effect of Peptide Caspase Inhibitors on Cell granule exocytosis pathway (data not shown).
Death Induced by Internalized Trypsin
One possible interpretation of the above results is that the lysis of these targets via granule exocytosis is due Discussion solely to perforin/cytolysin, while the apoptotic nuclear damage is due to granzymes acting via caspases. AlTaken together, these results show that target cell lysis though previous experiments with RBL transfectants induced by CTL via granule exocytosis is independent argue that granzymes are necessary for efficient target of caspases, even though apoptotic nuclear damage lysis (Nakajima et al., 1995c; induced by this pathway requires the activation of these 1994), we tested the ability of caspase inhibitors to block proteases. Several important controls add considerably apoptotic death induced by a purely proteolytic trigger.
to the strength of these conclusions. Lysis of both thyWhen tumor cell death was induced within 90 min by mocytes and tumor targets by other agents inducing cytoplasmic loading of trypsin via osmotic lysis of pinoapoptotic death was blocked by the peptide-FMK cassomes (Williams and Henkart, 1994), both peptide caspase inhibitors (Sarin et al., 1996 ; Figure 2 ), although pase inhibitors blocked apoptotic nuclear morphology lysis requires 12-16 hr rather than the 2-4 hr seen with ( Figure 4B ), but did not detectably inhibit target lysis as CTL. In addition, target lysis by the CTL-induced FasLjudged by trypan blue ( Figure 4A ). Thus, the death of Fas pathway in the 4 hr assay is blocked completely by these target cells triggered by internal tryptic proteolysis both types of caspase inhibitors using the same target behaves similarly to death induced by CTL granule exocells in experiments where the CTL granule exocytosiscytosis, with caspase inhibitors able to block nuclear induced lysis was not blocked. Thus, under the experidamage but not lysis. mental conditions used, lysis of the target cells was not inherently resistant to the caspase inhibitors. Furthermore, the inhibition of target nuclear damage by the Baculovirus p35 Blocks CTL-Induced Lysis via Fas but Not Granule Exocytosis granule exocytosis pathway shows that these inhibitors are active in the target cells during the cytotoxic proAlthough ZVAD-FMK and BD-FMK have been shown to block some caspases (Sarin et al., 1996) , it is possible cess, making it unlikely that target lysis via the granule exocytosis pathway involves caspases resistant to the that they fail to block other members of this family. We thus sought to confirm the results with peptide caspase inhibitors used. The specificity of caspase inhibitors used in these inhibitors using the baculovirus protein p35, a potent general blocker of caspases (Bump et al., 1995) . p35 was studies is critical to the conclusions drawn. The peptide-FMK inhibitors used appear to be specific for caspases expressed in tumor target cells by transient transfection, granule exocytosis pathway is unlikely to be due to a failure to inhibit functional caspases. We stress that we linked to, but not part of, the lysis pathway. This is (E and F) The cytotoxicity assay was identical to that in (A) and (B) based on the data presented and the demonstration except that Fas neg L1210 leukemia cells were targets and nuclear that enucleated and intact targets are equally sensitive damage was measured by DNA release using L1210 cells prelabeled to lysis by both granule exocytosis and Fas-FasL path-
with [ 3 H]thymidine. (G and H)
The CTL Fas pathway was tested in ways (Nakajima et al., 1995a) , as well as previous evithe same experiment as in (E) and (F) using a stable Fas transfectant subline of L1210 (Rouvier et al., 1993) . 51 Cr release data are shown dence for CTL killing in the absence of apoptotic nuclear as mean of triplicates with SEM.
damage (Nishioka and Welsh, 1992; Sellins and Cohen, 1991) . Caspases are shown as part of the Fas lytic pathway since caspase inhibitors block the Fas-based lysis.
Although not shown in Figure 6 , recent reports indicate based on the following: the peptide-FMKs used do not react with serine proteases, including granzyme B, unthat Fas-induced apoptotic mitochondrial damage is also blocked by caspase inhibitors (Krippner et al., 1996 ; der these conditions (Shaw, 1990; Sarin et al., 1996) ; all experiments included controls showing a lack of inhibi- Marchetti et al., 1996) , and since this damage may be required for other manifestations of apoptotic death tion with the homologous cathepsin inhibitor ZFA-FMK (Bromme et al., 1989) , which lacks an aspartic acid at (Marchetti et al., 1996) , it could be part of the CTLtriggered Fas death pathway. We do not know whether the P1 position; except for granzyme B, caspases are the only known aspartic acid-specific mammalian protethe same caspases are required for nuclear damage, mitochondrial damage, and lysis in the Fas pathway, nor ases. Studies on the mechanism of protease inhibition by baculovirus p35 indicate that a critical aspartic acidwhether these are identical to the caspase(s) required for nuclear damage by the granule exocytosis pathway. containing sequence in the protease is required for its inhibition (Bump et al., 1995; Xue and Horvitz, 1995) , This could explain why caspase activation by Fas leads to lysis while the granule exocytosis pathway gives only implying a stringent specificity for caspases. More importantly, achieving the same result with two completely caspase-dependent nuclear damage. Alternatively, a caspase-dependent lysis pathway triggered by granule different types of caspase inhibitors argues that the functional blocking achieved was attributable to casexocytosis could be slower than the noncaspase pathway that preempts it. In any case, an important goal of pase inhibition, and the failure to block lysis by the CTL lysis by granzyme B knockout CTL argues that caspase activation by this granule protease is not necessary for lysis (Darmon et al., 1996; Shresta et al., 1995; Heusel et al., 1994) . Our results with peptide-FMK inhibitors are consistent with recent studies showing that the CPP-32-like inhibitor AcDEVD-CHO blocked target DNA release but not lysis by CTL granule exocytosis (Darmon et al., 1996) .
The scheme in Figure 6 prompts a discussion of the common assumption that nuclear apoptotic damage is linked to cell death. The present results argue that, for the granule exocytosis pathway, nuclear damage resulting from caspase activation is unrelated to target cell death. While there can be little doubt that a cell that has undergone apoptotic nuclear damage will die, this can be preempted by more rapid lytic pathways. Thus, the presence of apoptotic nuclear damage in target cells does not necessarily mean that the actual cell death is a result of molecular pathways shared with other cases anti-CD3 antibody (10 ng/ml). After 4 hr, cells were harvested and nuclear damage as end points for death assays. Careful assayed for residual ␤-galactosidase activity as described previously (Memon et al., 1995) . To assay changes in nuclear morpholfunctional studies with caspase inhibitors may provide ogy (B), we stained pHook ϩ L1210 cells with di-I-C16 and Hoechst a more meaningful biochemical characterization of cell 33342. In (C), pHook ϩ L1210 target cells were prelabeled with death pathways than those based on classical apoptosis exceptions to this correlation exist. In any case, the results described in this paper point out that exclusive focus on apoptotic nuclear damage as an indicator of future research is to identify the nonnuclear downstream cell death is dangerous when considering functionally targets of both caspases and granzymes that lead to cell important death pathways. lysis. The diagram implies that the two death pathways converge, but since there are many ways to kill a cell, Experimental Procedures they may remain separate.
The scheme depicted in Figure 6 is consistent with The two distinct CTL death pathways are shown, with the granule exocytosis pathway depicted in solid arrows and the Fas-FasL pathway in broken lines and open arrowheads. Caspases are required for target cell death by the latter pathway and for nuclear damage via the granule exocytosis pathway, but not for death by the granule exocytosis pathway. In these rapid death processes, target nuclear damage does not participate in cell death. (1989) . The specificity of bovine spleen cathepsin Corp., Westbury, NJ) and used as effectors in cytotoxicity assays.
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